Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

WHO study, which was not 'blinded,' meaning that participants and their doctors were aware of which treatments were being used." Bloomberg (10/22, Langreth, 4.73M) reports the approval also allows "Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help so

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

used." Bloomberg <https://www.bloomberg.cotn/news/articles/2020-10-22/gilead-virus-therapy-remdesivir-gains- approval-from-fda?srnd-premium> (10/22, Langreth, 4.73M) reports the approval also allows "Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help so

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

WHO study, which was not `blinded,' meaning that participants and their doctors were aware of which treatments were being used." Bloomberg (10/22, Langreth, 4.73M) reports the approval also allows "Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help so